原名「台灣學術線上」
包含TAO期刊庫 + TAO書籍庫 + 論文 + 史料文獻
首頁 | 關於TAO | 瀏覽 | 進階查詢 | 參考工具 | 會員服務 | 已購專書 | RSS服務 | 電子報 | FAQ  
查詢範圍:
   
查詢模式:
熱門查詢詞:
老人需求dvdTaiwan vet雞濾泡顆粒細胞
   
   
   
     
   
 
項次 書目
1
題名:Concurrent Chemoradiotherapy Using Cisplatin and 5-Fluorouracil Alone or with Paclitaxel Followed by Adjuvant Cisplatin and 5-Fluorouracil in Nasopharyngeal Carcinoma    
單獨使用順鉑及有利癌或合併太平洋紫杉醇並同步放射治療對於鼻咽癌患者治療結果分析
著者:Jen-Cheng Lee(李仁正) ;Yi-Shing Leu(呂宜興) ;Jehn-Chuan Lee(李振川) ;Yi-Fang Chang(張義芳) ;Min-Jer Huang(黃明哲) ;Yu-Jen Chen(陳裕仁) ;Hong-Wen Chen(陳虹汶)
出版地區:台灣
出版城市:台北市
學科:醫學綜合
關鍵字:鼻咽癌 ; 同步化學放射治療 ; 太平洋紫杉醇 ; nasopharyngeal carcinoma ; concurrent chemoradiotherapy ; paclitaxel
刊名:Journal of the Chinese Oncology Society
頁碼:372-379
語言:英語
摘要: 中文摘要PDF ; 英文摘要PDF

背景:在鼻咽癌的治療上,目前最主要的治療方式是以同步執行化學治療及放射治療。而在化學治療的選擇上,最常被使用來治療鼻咽癌的是白金製劑(platinum-base agent)加上有利癌(5-fluorouracil)。而太平洋紫杉醇(Paclitaxel)被証實可用來治療復發及轉移的鼻咽癌。本回溯性研究分析即是針對這兩種不同的化學治療方式,提出治療結果整體存活率及無疾病存活率之比較。 方法:本研究採回溯性分析。自2002年1月至2004年12月,於馬偕紀念醫院頭頸癌治療團隊診斷為鼻咽癌的病人,累計共77例,接受同步執行化學治療及放射治療。在化學治療的藥劑當中,其中67例接受順鉑(cisplatin)加上有利癌治療(PF組),10例接受太平洋紫杉醇,順鉑加上有利癌治療(TPF組)。平均追蹤期間為43個月。 結果:本研究發現鼻咽癌患者整體的5年存活率約為72%,PF組及TPF組分別為71%及80%。而5年無疾病存活率PF組及TPF組分別為64%及70%。皆無統計學上的差異。 結論:本研究無法證實太平洋紫杉醇,在鼻咽癌患者同步執行化學治療及放射治療的好處。同步順鉑,有利癌及放射治療目前仍是鼻咽癌患者的首選治療。
Purpose: The purpose of this study was to analyze the treatment outcome of patients with nasopharyngeal carcinoma (NPC) treated with concurrent chemoradiotherapy (CCRT) with or without paclitaxel. Materials and Methods: Seventy-seven patients with NPC received treatment at Mackay Memorial Hospital from 2002 to 2004. All of patients were treated with CCRT. Sixty-seven patients received chemotherapy of cisplatin and 5-fluorouracil (PF arm), and 10 patients received chemotherapy of paclitaxel, cisplatin and 5-fluorouracil (TPF arm). All patients received adjuvant PF after CCRT. Kaplan-Meier estimates were calculated for the overall and disease-free survival rates. Log-rank test was used to determine significant difference between the two arms. Results: With a median follow-up of 43 months, 5-year overall survival rates (OS) and disease-free survival rates (DFS) for all patients were 72% and 65%, respectively. The 5-year OS in the PF arm and TPF arm were 71% and 80%, respectively (P=0.65). The 5-year DFS in the PF arm and TPF arm were 64% and 70%, respectively (P=0.61). There was no statistically significant difference between these two arms. Locoregional recurrence was found in 2 patients after the completion of treatment, and distant metastasis was found in 4 patients. Conclusions: Our study failed to demonstrate the benefit of adding paclitaxel in CCRT of NPC. Standard PF regimen incorporated into radiation is still the treatment of choice for NPC.


    

本卷期目次
Journal of the Chinese Oncology Society
胸腔鏡手術在肺癌治療之角色/ 劉會平
Pemetrexed Treatment in Non-Small Cell Lung Cancer Patients Failing Previous Platinum-based Chemotherapy and with/without Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment/ Yuh-Min ChenReury-Perng PerngChun-Ming TsaiJacqueline Whang-Peng
肺癌再次手術的臨床重要性/ 許南榮陳志毅
年齡增加在非小細胞肺癌使用Gefitinib治療是個預測因子/ 張基晟陳焜結楊宗穎林聖皓徐國軒
Concurrent Chemoradiotherapy Using Cisplatin and 5-Fluorouracil Alone or with Paclitaxel Followed by Adjuvant Cisplatin and 5-Fluorouracil in Nasopharyngeal Carcinoma/ Jen-Cheng LeeYi-Shing LeuJehn-Chuan LeeYi-Fang ChangMin-Jer HuangYu-Jen ChenHong-Wen Chen
合併肺小細胞癌及肺腺癌/ 葉裕民陳雅萍吳鴻昌蘇五洲
小細胞肺癌合併急性胰臟炎/ 吳鴻昌蘇五洲
Delirium as the Abrupt Manifestation of Severe Anaphylactic Reaction to Oxaliplatin/ Yi-Ying WuPing-Ying ChangHsuen-Fu LinYeu-Chin ChenWei-Yau KaoTsu-Yi ChaoChing-Liang Ho
Multiple Recurrent Meningiomas with Malignant Transformation and Radiation Encephalopathy/ Chih-Pei HsuCheng-Kuei Chang
Myeloid Sarcoma of the Ileum/ Chi YangMeng-Yi TsaiChiang-Chin Tsai
 
   
 
   

與TAO合作 | 隱私與版權聲明 | 聯絡方式 | 下載Adobe Reader
地址:台北市中正區(100)北平東路30-12號3樓
電話:(02)2393-6968 傳真:(02)2393-6877
Email: service@wordpedia.com
Wordpedia Family: 學校、企業版入口 | 遠流影音館
Copyright©2011 Wordpedia Co., Ltd. All Rights Reserved.